Cost & Value of MedicinesShare the Savings

Patients share the costs for their medicines. They should share the savings, too.

Robust negotiations between biopharmaceutical companies and insurers often result in significant rebates and discounts. According to a recent study from the Berkeley Research Group, more than a third of the list price for brand medicines is rebated back to payers and the supply chain.

However, unlike care received at an in-network hospital or physician’s office, negotiated discounts for medicines are not shared with patients with high deductibles or coinsurance. A new analysis from Amundsen Consulting found more than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on the full list price. 

Insurers should share more of these rebates with patients.  Providing access to discounted prices at the point-of-sale could dramatically lower patients’ out-of-pocket costs.

Get the facts and find out where the discounts are going.

 

Ads

Ads

Graphics

Reports

Reports

Latest From TheCatalyst Blog

By Robert Zirkelbach on June 24, 2019

By Katie Koziara on June 21, 2019

By Lauren Neves on June 20, 2019

By Holly Campbell on June 12, 2019
силденафил инструкция по применению

варденафил дапоксетин

avana